Portola Pharmaceuticals, Inc.

Portola Pharmaceuticals, Inc. operates as a biopharmaceutical company that develops and commercializes novel therapeutics in the areas of thrombosis and other hematologic disorders and inflammation in Europe and the United States. It produces Andexxa, an antidote for the treatment of rivaroxaban and apixaban under the Ondexxya brand; Bevyxxa (betrixaban), an oral, once-daily Factor Xa inhibitor for the prevention of venous thromboembolism in adult patients for an acute medical illness; cerdulatinib, an investigational oral, dual spleen tyrosine kinase; and Janus kinases inhibitor for the treatment of hematologic cancers. The company was incorporated in 2003 and is based in South San Francisco, California. As of July 1, 2020, Portola Pharmaceuticals, Inc. operates as a subsidiary of Alexion Pharmaceuticals, Inc.